title: Management of bullous pemphigoid with topical steroids in the clinical practice of a single center: outcome at 6 and 12 months.
abstract: BACKGROUND
  The efficacy of topical steroids in bullous pemphigoid (BP) was assessed by prospective therapeutic trials. Systemic corticosteroids and immunosuppressant agents are indicated in situations of failure or relapses.
  
  
  OBJECTIVE
  To report our experience in the management of BP outside therapeutic trials focusing on the outcome of the patients at 6 and 12 months, compliance and follow-up difficulties.
  
  
  METHODS
  Monocenter retrospective study with collection of clinical, therapeutic and follow-up data after 6 and 12 months.
  
  
  RESULTS
  Ninety-six patients, mean age 84 years, 65 females, 54% had neurological impairment. The initial dose of clobetasol propionate was 30 g/day, followed by a progressive decrease. In the first 6 months, 14% were lost to follow-up and 17.7% died; 62% were controlled with topical steroids alone, and 25% had adjunctive systemic treatment. Difficulties of compliance were mentioned in 34.4%, without significant difference between controlled and noncontrolled patients. After 12 months, 23% were lost to follow-up and 27.1% died. The mean duration of the treatment was 11.7 ± 8.4 months. After the stop, 18.9% of patients relapsed within 3 months.
  
  
  CONCLUSIONS
  We emphasize the frequent recourse to systemic treatments in the first few months, the difficulties of compliance and of follow-up in our day-to-day experience.
authors: Service de Dermatologie, Université Paris-Est Créteil Val de Marne, Créteil, France. saskia.oro@hmn.aphp.fr
authors: S
authors: S
authors: Ingen-Housz-Oro
authors: L
authors: L
authors: Valeyrie-Allanore
authors: N
authors: N
authors: Ortonne
authors: J C
authors: JC
authors: Roujeau
authors: P
authors: P
authors: Wolkenstein
authors: O
authors: O
authors: Chosidow
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002990:Clobetasol / Q000627:therapeutic use*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D059012:Lost to Follow-Up; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D010349:Patient Compliance; D010391:Pemphigoid, Bullous / Q000188:drug therapy*; D012008:Recurrence; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D002990:Clobetasol; D009173:Mycophenolic Acid; D008727:Methotrexate